Cargando…
Metabolomic biomarkers for hepatocellular carcinoma: A systematic review
Background: Hepatocellular carcinoma (HCC) is a highly malignant cancer which lack of effective diagnosis and prognosis biomarkers, therefore surging studies focused on the metabolite candidates for HCC. The current study was designed to systematically review the metabolic studies for HCC, summarize...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772637/ https://www.ncbi.nlm.nih.gov/pubmed/35060504 http://dx.doi.org/10.1097/MD.0000000000028510 |
_version_ | 1784635888809017344 |
---|---|
author | Feng, Ningning Yu, Fatao Yu, Feng Feng, Yuling Zhu, Xiaolin Xie, Zhihui Zhai, Yi |
author_facet | Feng, Ningning Yu, Fatao Yu, Feng Feng, Yuling Zhu, Xiaolin Xie, Zhihui Zhai, Yi |
author_sort | Feng, Ningning |
collection | PubMed |
description | Background: Hepatocellular carcinoma (HCC) is a highly malignant cancer which lack of effective diagnosis and prognosis biomarkers, therefore surging studies focused on the metabolite candidates for HCC. The current study was designed to systematically review the metabolic studies for HCC, summarize the current available evidence and provide implication for further studies within this area. By systematically screening Pubmed and Embase, and eligibility assessment, we eventually included 55 pieces of studies. After summarized their characteristics, we reviewed them by 3 parts, regarding to the different biofluid they carried out the experiments. By collecting the candidates from all the included studies, we carried out pathway enrichment to see the representative of the reported candidates, as expected the pathway consistent with the current knowledge of HCC. Next, we conduct quality assessment on the included studies. Only 36% of the current evidence grouped as high quality, indicating the quality of metabolic studies needs further improvement. |
format | Online Article Text |
id | pubmed-8772637 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-87726372022-01-21 Metabolomic biomarkers for hepatocellular carcinoma: A systematic review Feng, Ningning Yu, Fatao Yu, Feng Feng, Yuling Zhu, Xiaolin Xie, Zhihui Zhai, Yi Medicine (Baltimore) 4500 Background: Hepatocellular carcinoma (HCC) is a highly malignant cancer which lack of effective diagnosis and prognosis biomarkers, therefore surging studies focused on the metabolite candidates for HCC. The current study was designed to systematically review the metabolic studies for HCC, summarize the current available evidence and provide implication for further studies within this area. By systematically screening Pubmed and Embase, and eligibility assessment, we eventually included 55 pieces of studies. After summarized their characteristics, we reviewed them by 3 parts, regarding to the different biofluid they carried out the experiments. By collecting the candidates from all the included studies, we carried out pathway enrichment to see the representative of the reported candidates, as expected the pathway consistent with the current knowledge of HCC. Next, we conduct quality assessment on the included studies. Only 36% of the current evidence grouped as high quality, indicating the quality of metabolic studies needs further improvement. Lippincott Williams & Wilkins 2022-01-21 /pmc/articles/PMC8772637/ /pubmed/35060504 http://dx.doi.org/10.1097/MD.0000000000028510 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | 4500 Feng, Ningning Yu, Fatao Yu, Feng Feng, Yuling Zhu, Xiaolin Xie, Zhihui Zhai, Yi Metabolomic biomarkers for hepatocellular carcinoma: A systematic review |
title | Metabolomic biomarkers for hepatocellular carcinoma: A systematic review |
title_full | Metabolomic biomarkers for hepatocellular carcinoma: A systematic review |
title_fullStr | Metabolomic biomarkers for hepatocellular carcinoma: A systematic review |
title_full_unstemmed | Metabolomic biomarkers for hepatocellular carcinoma: A systematic review |
title_short | Metabolomic biomarkers for hepatocellular carcinoma: A systematic review |
title_sort | metabolomic biomarkers for hepatocellular carcinoma: a systematic review |
topic | 4500 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772637/ https://www.ncbi.nlm.nih.gov/pubmed/35060504 http://dx.doi.org/10.1097/MD.0000000000028510 |
work_keys_str_mv | AT fengningning metabolomicbiomarkersforhepatocellularcarcinomaasystematicreview AT yufatao metabolomicbiomarkersforhepatocellularcarcinomaasystematicreview AT yufeng metabolomicbiomarkersforhepatocellularcarcinomaasystematicreview AT fengyuling metabolomicbiomarkersforhepatocellularcarcinomaasystematicreview AT zhuxiaolin metabolomicbiomarkersforhepatocellularcarcinomaasystematicreview AT xiezhihui metabolomicbiomarkersforhepatocellularcarcinomaasystematicreview AT zhaiyi metabolomicbiomarkersforhepatocellularcarcinomaasystematicreview |